Hemostemix Inc. (CVE:HEM – Get Free Report) shares fell 17.1% during mid-day trading on Wednesday . The stock traded as low as C$0.28 and last traded at C$0.32. 605,102 shares traded hands during mid-day trading, a decline of 8% from the average session volume of 658,279 shares. The stock had previously closed at C$0.38.
Hemostemix Trading Down 17.1 %
The firm has a 50-day moving average of C$0.14 and a two-hundred day moving average of C$0.10. The firm has a market capitalization of C$27.44 million, a PE ratio of -15.75 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Steel Stocks Soaring After Tariff Announcements
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- Why Are Stock Sectors Important to Successful Investing?
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
